Outcome for Board Meeting held today for approving Audited Financials and Recommending Final Dividend.
MEDANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts more than Nifty Midcap 150 and 2.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Global Health Limited (Medanta) reported strong full-year FY2026 consolidated results. Total income grew to ₹45,088.60 million from ₹37,712.92 million in FY2025, representing approximately 19.4% year-on-year revenue growth. Profit after tax (PAT) stood at ₹5,540.68 million versus ₹4,813.18 million in the prior year, a growth of about 15%. The company recorded exceptional items of ₹10.21 million net (including ₹365.98 million impact from new Labour Codes, partially offset by EPCG reversal of ₹195.92 million and stamp duty reversal of ₹159.85 million). The statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion with no audit qualifications. The Board recommended a final dividend of ₹0.50 per equity share (25% on face value of ₹2). Additionally, the company announced a new 400-bed multi-specialty hospital in Varanasi and a Business Transfer Agreement for a 79-bed oncology hospital in Indore.
The company delivered ~20% revenue growth with healthy profitability expansion. Clean audit opinion and dividend declaration are positive signals for shareholders. New hospital expansions signal growth focus.